Table 1 Baseline characteristics of patients in the SCarlet RoAD study
From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Variable | Intention-to-treat population (n = 797) | ||
|---|---|---|---|
Placebo (n = 266) | Gantenerumab 105 mg (n = 271) | Gantenerumab 225 mg (n = 260) | |
Age, years, mean (SD) | 69.5 (7.5) | 70.3 (7.0) | 71.3 (7.1) |
Education, years, mean (SD) | 89.8% | 93.0% | 91.9% |
Weight, kg, mean (SD) | 12.6 (4.3) | 12.9 (4.8) | 12.1 (4.5) |
APOE ε4 genotype, %a | 69.8 (12.9) | 70.5 (13.6) | 70.1 (12.5) |
0ε4 | 29.7% | 21.0% | 38.5% |
1ε4 | 50.4% | 41.0% | 61.5% |
2ε4 | 19.9% | 38.0% | – |
Clinical scores | |||
CDR-SB, mean score (SD) | 2.1 (1.0) | 2.2 (1.0) | 2.0 (0.9) |
ADAS-Cog 13, mean score (SD) | 23.5 (7.2) | 23.1 (6.9) | 23.0 (6.2) |
FAQ, mean score (SD) | 4.9 (4.3) | 4.6 (3.9) | 4.8 (4.3) |
FCSRT-Total Recall, mean score (SD) | 29.3 (10.8) | 28.3 (10.8) | 30.5 (10.4) |
MMSE, mean score (SD) | 25.7 (2.1) | 25.7 (2.3) | 25.7 (2.2) |
CSF biomarkers | |||
Aβ42, pg/ml, mean (SD) | 487.8 (170.4) | 475.3 (142.2) | 511.8 (172.0) |
t-tau, pg/ml, mean (SD) | 556.3 (203.8) | 563.2 (239.1) | 544.5 (220.5) |
p-tau, pg/ml, mean (SD) | 84.0 (31.4) | 86.3 (39.5) | 82.5 (34.2) |
Neurogranin, pg/ml, mean (SD) | 474.8 (260.7) | 500.5 (270.0) | 484.9 (293.9) |